Acorda Therapeutics (OTCPK:ACOR.Q) - Prezzo delle azioni, notizie e analisi

ACOR.Q Panoramica delle azioni

A biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. Maggiori dettagli

ACOR.Q analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	0/6
Salute finanziaria	0/6
Dividendi	0/6

Analisi del rischio

Non ha una capitalizzazione di mercato significativa ( $37K )

Ha meno di 1 anno di pista di cassa

Prezzo delle azioni altamente volatile negli ultimi 3 mesi

Patrimonio netto negativo

Acorda Therapeutics, Inc. Concorrenti

Athenex

OTCPK:ATNX.Q

US$131.7k

Peak Bio

OTCPK:PKBO

US$1.6m

Endonovo Therapeutics

OTCPK:ENDV

US$317.5k

International Stem Cell

OTCPK:ISCO

US$960.5k

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Acorda Therapeutics
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$0.02
Massimo di 52 settimane	US$18.00
Minimo di 52 settimane	US$0.013
Beta	1.69
1Variazione di 1 mese	-84.62%
Variazione a 3 mesi	-96.88%
Variazione di 1 anno	-99.88%
3Variazione a 3 anni	-99.97%
Variazione a 5 anni	-99.99%
Variazione dall'IPO	-100.00%

Notizie e aggiornamenti recenti

Recent updates

Health Check: How Prudently Does Acorda Therapeutics (NASDAQ:ACOR) Use Debt?

Feb 21

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Surges 53% Yet Its Low P/S Is No Reason For Excitement

Dec 18

Is Acorda Therapeutics (NASDAQ:ACOR) Using Debt Sensibly?

Jun 05

Acorda wins $16.5M in Ampyra arbitration case with Alkermes

Oct 17

Acorda stock rise 11% as proposal to increase shares withdrawn; reverse split still on vote

Oct 10

CureVac downgraded following COVID vaccine data, Regeneron COVID cocktail a boon, and more in analyst action

Jun 17

Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For Now

May 26

Acorda Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Sole Analyst Just Made A Huge Upgrade To Their Forecasts

Mar 09

Rendimenti per gli azionisti

	ACOR.Q	US Biotechs	US Mercato
7D	-28.5%	4.0%	2.0%
1Y	-99.9%	18.0%	32.4%

Ritorno vs Industria: ACOR.Q ha avuto una performance inferiore rispetto al US Biotechs che ha registrato un rendimento 18 % nell'ultimo anno.

Rendimento vs Mercato: ACOR.Q ha avuto una performance inferiore al mercato US che ha registrato un rendimento 32.4 % nell'ultimo anno.

Volatilità dei prezzi

Is ACOR.Q's price volatile compared to industry and market?
ACOR.Q volatility
ACOR.Q Average Weekly Movement	55.6%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.9%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: Il prezzo delle azioni di ACOR.Q è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale di ACOR.Q è aumentata da 34% a 56% nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1995	102	Ron Cohen	www.acorda.com

Acorda Therapeutics, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Acorda Therapeutics con la sua capitalizzazione di mercato?
ACOR.Q statistiche fondamentali
Capitalizzazione di mercato	US$37.39k
Guadagni(TTM)	-US$263.42m
Ricavi(TTM)	US$115.66m

0.0x

Rapporto P/S

0.0x

Rapporto P/E

ACOR.Q è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
ACOR.Q Conto economico (TTM)
Ricavi	US$115.66m
Costo del fatturato	US$20.48m
Profitto lordo	US$95.19m
Altre spese	US$358.61m
Guadagni	-US$263.42m

Ultimi guadagni dichiarati

Mar 31, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-212.08
Margine lordo	82.30%
Margine di profitto netto	-227.75%
Rapporto debito/patrimonio netto	-103.1%

Come si è comportato ACOR.Q nel lungo periodo?

Vedi performance storica e confronto

ACOR.Q Panoramica delle azioni

Analisi del rischio

Acorda Therapeutics, Inc. Concorrenti

OTCPK:ATNX.Q

US$131.7k

OTCPK:PKBO

US$1.6m

OTCPK:ENDV

US$317.5k

OTCPK:ISCO

US$960.5k

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc.

Acorda Therapeutics Files Form 15

Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million.

Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc.

Nasdaq Files Form 25 with the U.S. Securities and Exchange Commission to Delist Acorda Therapeutics's Common Stock from Nasdaq, Effective on May 5, 2024

Acorda Therapeutics Announces Delisting from Nasdaq

Recent updates

First Motion for Exclusivity Period Extension Approved For Acorda Therapeutics, Inc.

Acorda Therapeutics Files Form 15

Merz Pharmaceuticals, LLC completed the acquisition of Substantially all of the assets of Acorda Therapeutics, Inc. for approximately $190 million.

Solicitation Version of First amended Disclosure Statement Approved for Acorda Therapeutics, Inc.

Nasdaq Files Form 25 with the U.S. Securities and Exchange Commission to Delist Acorda Therapeutics's Common Stock from Nasdaq, Effective on May 5, 2024

Acorda Therapeutics Announces Delisting from Nasdaq

Acorda Therapeutics, Inc.(OTCPK:ACOR.Q) dropped from NASDAQ Composite Index

Motion for Asset Sale Filed by Acorda Therapeutics, Inc.

Merz Pharmaceuticals, LLC entered into an asset purchase agreement to acquire Substantially all of the Companys assets of Acorda Therapeutics, Inc. for approximately $190 million.

Acorda Therapeutics, Inc. Filed for Bankruptcy

Acorda Therapeutics, Inc. to Report Q4, 2023 Results on Apr 01, 2024

Health Check: How Prudently Does Acorda Therapeutics (NASDAQ:ACOR) Use Debt?

New minor risk - Share price stability

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Surges 53% Yet Its Low P/S Is No Reason For Excitement

Third quarter 2023 earnings released: US$7.16 loss per share (vs US$11.41 loss in 3Q 2022)

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2023

Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA

New minor risk - Shareholder dilution

Acorda Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2023

Second quarter 2023 earnings released: US$7.55 loss per share (vs US$55.63 loss in 2Q 2022)

Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Acorda Therapeutics Announces Completion of Reverse Stock Split to Enable the Company to Regain Compliance with the Minimum Closing Price Required to Maintain Continued Listing on the Nasdaq Global Select Market

Is Acorda Therapeutics (NASDAQ:ACOR) Using Debt Sensibly?

Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split to Regain Compliance with the Minimum Closing Price Required to Maintain Continued Listing

First quarter 2023 earnings released: US$0.69 loss per share (vs US$1.85 loss in 1Q 2022)

Acorda Therapeutics, Inc. Reaffirms Earnings Guidance for the Year 2023

Full year 2022 earnings released: US$3.35 loss per share (vs US$9.79 loss in FY 2021)

Acorda Therapeutics Receives Nasdaq Extension to Meet Minimum Bid Price Requirement

Acorda Therapeutics Receives Nasdaq Listing Determination Letter and Plans to Request A Hearing

Third quarter 2022 earnings released: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.57 loss per share (vs US$2.43 loss in 3Q 2021)

Acorda Therapeutics, Inc. Provides Earnings Guidance for the Years of 2022, 2023, 2024, 2025, 2026 and 2027

Acorda Therapeutics, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Acorda wins $16.5M in Ampyra arbitration case with Alkermes

Acorda stock rise 11% as proposal to increase shares withdrawn; reverse split still on vote

Acorda inks license deal with Asieris for pre-clinical drug

Acorda Therapeutics Announces Resignation of Lauren Sabella as Chief Operating Officer

Acorda Therapeutics announces resignation of COO

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2022

Second quarter 2022 earnings released: US$2.78 loss per share (vs US$2.29 loss in 2Q 2021)

Acorda Therapeutics Receives Deficiency Letter Listing Qualifications Department of Nasdaq Stock Market

Acorda Therapeutics, Inc. Provides Revenue Guidance for the Year 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Insufficient new directors

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Acorda Therapeutics, Inc. Announces Board Changes

Insufficient new directors

Third quarter 2021 earnings released: US$2.43 loss per share (vs US$0.92 profit in 3Q 2020)

Acorda Therapeutics: Managing The Transition

Independent Director Barry Greene has left the company

Independent Director Catherine D. Strader has left the company

Second quarter 2021 earnings released: US$2.29 loss per share (vs US$2.19 loss in 2Q 2020)

Acorda Therapeutics Continues To Maneuver For A Turnaround

CureVac downgraded following COVID vaccine data, Regeneron COVID cocktail a boon, and more in analyst action

Shareholders May Be More Conservative With Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Compensation For Now

First quarter 2021 earnings released: US$3.53 loss per share (vs US$0.81 loss in 1Q 2020)

Acorda Therapeutics, Inc. Provides Financial Guidance for the Full Year of 2021

Acorda Therapeutics, Inc. 2021 Q1 - Results - Earnings Call Presentation

Analysts increase revenue estimates to US$95.7m